Skip to content
DE

SemaxExperimental neuroactive peptide

Semax is a synthetic peptide related to a fragment of ACTH. It has been investigated in neurological settings and is also marketed much more broadly for focus and cognition.

What is Semax?

Semax is a synthetic ACTH-related peptide investigated in neurological settings. Claims for healthy-person focus extend beyond the same question as treatment after stroke or during illness.

How it works

Laboratory work has examined nerve-growth signals, inflammation and injury responses. These proposed pathways do not directly measure everyday memory or concentration. 1

Effects studied

Neurological recovery and cognition

The retained material describes preclinical findings and a geographically concentrated clinical literature. Results need diagnosis-specific assessment of comparators, masking and replication before supporting broad cognitive claims.

Evidence: Preclinical work and limited clinical reports

What does the evidence show?

The archive describes preclinical mechanisms and a geographically concentrated clinical literature. Independent replication and relevance to the advertised use remain central questions.

What researchers are trying to change

Semax was developed from an ACTH-related sequence while aiming for effects different from the parent hormone. Laboratory work has examined nerve-growth signals, inflammation and responses to injury. These are possible explanations to test, rather than direct measurements of clearer thinking or better memory in daily life. 1

A diagnosis changes the question

Recovery after stroke, cognitive symptoms during illness and performance in a healthy person require different studies. Baseline health, outcomes and accompanying treatments differ. Grouping them under “nootropic” obscures whether a result applies to the person or purpose in question.

Reading the evidence fairly

A study’s country or language does not determine its quality. Randomisation, masking, a suitable comparison, complete reporting and replication matter. The small clinical reports in the archive need assessment on those terms. A plausible mechanism alone cannot turn them into a general recommendation.

The preparation also matters

Nasal preparations and products sold for injection cannot be assumed equivalent. An advertised concentration does not establish delivered dose or product quality. Semax and Selank are also distinct molecules, despite frequently appearing together in marketing. This page makes no current approval claim for Germany or Switzerland.

Safety & status

Nasal preparations and injected products have different exposure and quality questions. Current German or Swiss approval is not established by this entry.

Country and product status

This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.

Frequently asked questions

Is Semax the same as Selank?

No. They are distinct molecules derived from different starting peptides.

Do stroke studies show it improves focus in healthy people?

No. Baseline health, accompanying care and the outcomes being measured differ.

Further reading

A balance holds a bead chain on one side and a clear lens on the other.GuideSemax: mechanism of action, studies and open questionsSemax is used in Russia but is not approved in the US. What the available studies say, and where independent evidence is missing.Read the article

Sources

This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.

  1. Semax: paper 10.1016/j.npep.2020.102114 Research reference · Retained archive reference; not independently checked for this draft.
  2. Semax: www.statnews.com reference Reference or product information · Retained archive reference; not independently checked for this draft.
  3. Semax: paper 10.1002/dta.2717 Research reference · Retained archive reference; not independently checked for this draft.
  4. Semax: paper 10.1007/s10571-009-9432-0 Research reference · Retained archive reference; not independently checked for this draft.
Research provenance

This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.